In 2014, one year after the formation of the MBC Alliance, we published Changing the Landscape for People Living with Metastatic Breast Cancer. Chapter 5 of the analysis showed a lack of data about the population of metastatic breast cancer (MBC) patients living across the US. We identified key questions to be answered about MBC
NEW YORK, October 13, 2018 – Today, the Metastatic Breast Cancer Alliance launched MBC Connect, a free mobile and web-based tool for patients with metastatic breast cancer (MBC) that will build a powerful database of patient information to help drive research, discoveries, and advances for the MBC community. MBC Connect provides access to an interactive
Looking for a clinical trial? BreastCancerTrials.org (BCT) recently launched an upgraded version of Metastatic Trial Search (MTS) with improved search and filtering options. Now patients have even more customizable options for finding clinical trials. BCT also just launched Metastatic Trial Talk (MTT), a new companion application that provides patients with carefully selected news and features about metastatic breast cancer research.
Researchers in clinical oncology and other domains generally focus on results encompassing a statistical mean with little attention to patients undergoing investigational or standard therapies who respond considerably better or worse than the norm.
What proportion of MBC patients are de novo vs recurrent? Currently, the Surveillance, Epidemiology and End Results Program, or SEER, provides extensive information regarding cancer diagnosis and some data regarding primary treatment and survival, but it does not collect information on metastatic cancer recurrence.